---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-076633"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:46:21.840677+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuCell swings to Q2 profit of $502k on 18% sales growth to $6.4M

## Summary
- Q2 product sales $6.4M, up 18% YoY; H1 sales $14.5M, up 14%.
- Net income $502k ($0.06/diluted) vs loss of ($1.5M) in Q2 2024.
- Gross margin improved to 44% from 22%; adjusted EBITDA $1.4M in Q2.
- Cash rose to $6.0M from $3.8M at Dec 2024; no line-of-credit draws.
- Re-Tain: initiating field feedback, reducing R&D spend, exploring strategic options.

## SEC filing metadata
- accession: 0001213900-25-076633
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390025076633/0001213900-25-076633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390025076633/ea0253265-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-076633
- JSON: https://secwatch.observer/filing/0001213900-25-076633.json
- Plain text: https://secwatch.observer/filing/0001213900-25-076633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.